Kintara Therapeutics, Inc. (NasdaqCM:KTRA) is continuing to evaluate strategic options with the goal of maximizing shareholder value. Kintara Therapeutics announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value and has engaged Ladenburg Thalmann & Co. Inc. to act as financial advisor for this process (December 2023).

Robert E. Hoffman, Kintara's President and Chief Executive Officer commented that 'We have strengthened our balance sheet primarily with net proceeds from our at-the-market (ATM) facility and aggressive cost-cutting efforts. We continue to evaluate strategic options with the goal of maximizing shareholder value'.